TEDI, more commonly written as TED, stands for Thyroid Eye Disease. It’s an autoimmune condition where the immune system attacks the tissues around the eyes, causing swelling, bulging, pain, and sometimes vision problems. Though rare in the general population, TED is the most common inflammatory disorder of the eye socket and affects more than 50% of people with Graves’ disease at some point during their illness.
How TED Connects to Thyroid Problems
About 90% of TED cases occur in people with Graves’ disease, an autoimmune condition that causes the thyroid gland to become overactive. The two conditions share a root cause: the immune system produces antibodies that mistakenly target healthy tissue. In the thyroid, these antibodies overstimulate hormone production. In the eyes, they trigger inflammation in the muscles, fat, and connective tissue behind and around the eyeball.
The timing varies. In roughly 65% of patients, eye symptoms show up within six months of a thyroid diagnosis. Another 20% develop eye problems between 7 and 24 months later, and about 15% don’t notice eye changes until more than two years after their thyroid condition was identified. TED can also appear before any thyroid abnormality is detected, or even in people with normal or low thyroid function, which can make the initial diagnosis confusing.
What TED Looks and Feels Like
The earliest symptoms are often easy to dismiss: a gritty, foreign-body sensation in the eyes, dryness, and excessive tearing. These happen because inflammation disrupts the tear film and damages the glands that keep the eye surface moist.
The most common visible sign is upper eyelid retraction, where the eyelid pulls back to expose more of the white of the eye. This occurs in over 90% of people with TED. The second hallmark is proptosis, the medical term for eyes that bulge forward, which affects about 60% of patients. Swollen muscles and expanding fat tissue behind the eye push it outward within the bony eye socket.
Other symptoms include:
- Double vision (diplopia): Affects about 40% of patients due to swollen, stiff eye muscles that can’t move in sync. It tends to be worse in the morning and fluctuates during active disease.
- Dull, pressure-like eye pain: Reported by about 30% of patients, sometimes worsening with eye movement.
- Puffy eyelids and redness: Caused by congested veins in the eye socket. Morning puffiness around the eyes is a classic early sign.
- Conjunctival swelling (chemosis): The clear membrane over the white of the eye balloons outward, seen in 15% to 25% of moderate to severe cases.
The Active and Inactive Phases
TED follows a predictable pattern sometimes called the Rundle curve. It begins with an active inflammatory phase where symptoms escalate, followed by an inactive phase where inflammation subsides but physical changes remain.
The active phase lasts anywhere from 6 months to 5 years, with an average of about 2 years. During this window, the immune system is actively inflaming the eye socket tissues. Muscles swell and accumulate scar-like material. Fat tissue expands. The rising pressure inside the bony orbit pushes the eyes forward, compresses veins, and traps inflammatory molecules in a self-reinforcing cycle. This is the critical treatment window: aggressive management during the active phase can limit long-term damage.
After roughly 18 months of activity, most people enter the inactive or “burnout” phase. Inflammation quiets down, but the structural changes it caused, including scarred muscles, repositioned fat, and retracted eyelids, typically don’t fully reverse on their own. At this stage, medications aimed at reducing inflammation no longer help, and surgical correction becomes the primary option for residual problems.
When Vision Is at Risk
The most serious complication of TED is optic neuropathy, where swollen muscles compress the nerve that carries visual signals from the eye to the brain. It’s the leading cause of blindness in TED patients. Warning signs include blurred vision, faded color perception, and visual field loss, though no single symptom reliably predicts it. More than a third of patients later confirmed to have optic nerve compression didn’t have significant eye bulging or high inflammation scores at the time, meaning it can develop even when other symptoms seem mild.
Corneal damage is another concern. When the eyelids can’t fully close over a bulging eye, the exposed cornea dries out and can develop ulcers. Elevated pressure inside the eye socket can also raise pressure within the eye itself, increasing the risk of glaucoma.
What Causes It at the Cellular Level
The tissue behind your eyes contains specialized cells called orbital fibroblasts. In TED, immune cells, particularly certain white blood cells called B lymphocytes, interact with these fibroblasts through a receptor on their surface that normally responds to a growth hormone signal. When this receptor is activated inappropriately, the fibroblasts produce large amounts of a gel-like substance that absorbs water and swells, while also generating inflammatory chemicals that recruit more immune cells. The result is a snowball effect of swelling, fluid retention, and tissue expansion confined within the rigid walls of the eye socket.
How Doctors Assess Severity
Doctors use a scoring system called the Clinical Activity Score to determine whether TED is still in its active phase. The initial version checks seven items: two related to pain (spontaneous pain behind the eye and pain when looking around) and five visible signs of inflammation (red eyelids, bloodshot conjunctiva, swollen caruncle, puffy eyelids, and chemosis). Each item scores one point, and a total of 3 or more indicates active disease. A follow-up version adds three more items tracking worsening over time: increasing eye bulging, decreasing eye movement, and declining visual sharpness.
Smoking and Other Risk Factors
Smoking is the single most significant modifiable risk factor for TED. Smokers face roughly 7.7 times the odds of developing the condition compared to nonsmokers, and the number of cigarettes smoked per day independently predicts the severity of eye bulging and double vision. Smoking also makes treatment less effective. Studies have shown that smokers respond more poorly to standard anti-inflammatory therapies than nonsmokers, with less improvement in both soft tissue swelling and eye muscle function.
Treatment During the Active Phase
Because the active phase is when damage accumulates, treatment focuses on suppressing inflammation before permanent scarring sets in. A targeted therapy that blocks the growth-factor receptor on orbital fibroblasts has shown strong results in clinical trials. In one study, 83% of treated patients achieved a reduction in eye bulging of 2 millimeters or more after 24 weeks, compared to just 10% of those receiving a placebo. The average reduction was 3.32 millimeters, and improvement occurred regardless of how severe the bulging was at the start.
Milder cases are often managed with lubricating eye drops, cool compresses, and prism glasses to correct double vision while waiting for the active phase to pass.
Surgery After the Disease Stabilizes
Once TED enters the inactive phase and has been stable for at least several months, surgery can address the structural damage left behind. The standard approach follows a specific sequence: orbital decompression first, then eye muscle surgery, then eyelid adjustment. This order matters because each procedure changes the anatomy in ways that affect the next.
Orbital decompression removes bone or fat from the eye socket to create more room, pushing the eye back into a more normal position. It’s done urgently when the optic nerve is being compressed, the cornea is severely damaged, or the eye is at risk of displacing forward out of the socket. In less urgent situations, it’s performed electively to relieve persistent bulging, pain, or elevated eye pressure. After decompression, strabismus surgery can realign the eye muscles to correct double vision, and eyelid surgery can fix retraction so the lids close properly again.